BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14555336)

  • 1. Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.
    Springer D; Staack RF; Paul LD; Kraemer T; Maurer HH
    Xenobiotica; 2003 Oct; 33(10):989-98. PubMed ID: 14555336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes.
    Springer D; Staack RF; Paul LD; Kraemer T; Maurer HH
    Xenobiotica; 2005 Mar; 35(3):227-37. PubMed ID: 16019948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
    Springer D; Paul LD; Staack RF; Kraemer T; Maurer HH
    Drug Metab Dispos; 2003 Aug; 31(8):979-82. PubMed ID: 12867484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
    Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
    Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
    Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
    Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.
    Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
    Xenobiotica; 2004 Feb; 34(2):179-92. PubMed ID: 14985146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
    Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
    J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone.
    Peters FT; Meyer MR; Theobald DS; Maurer HH
    Drug Metab Dispos; 2008 Jan; 36(1):163-8. PubMed ID: 17962373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.
    Jang GR; Wrighton SA; Benet LZ
    Biochem Pharmacol; 1996 Sep; 52(5):753-61. PubMed ID: 8765473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
    Johnson JA; Herring VL; Wolfe MS; Relling MV
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
    VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
    Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
    Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
    Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
    Seguin RP; Herron JM; Lopez VA; Dempsey JL; Xu L
    Chem Res Toxicol; 2019 Dec; 32(12):2466-2478. PubMed ID: 31730751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes.
    Sudsakorn S; Skell J; Williams DA; O'Shea TJ; Liu H
    Drug Metab Dispos; 2007 Jun; 35(6):841-7. PubMed ID: 17332142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.